Synaffix BV today announces it has licensed its #ADC technology to BigHat Biosciences. BigHat will combine Synaffix technology with its world-class machine learning #antibody design platform for the development of a new ADC pipeline program. Under the terms of the agreement, BigHat will receive target-specific access to Synaffix’s late-clinical stage, site-specific ADC technology platform, which enables the transformation of antibodies into proprietary, best-in-class ADC products. BigHat will also gain access to Lonza’s end-to-end ADC offering. For more information on this exciting new collaboration, please read the full press release linked in the comments below. #ADCs #drugdevelopment #innovation #artificialintelligence #machinelearning
Congrats, Synaffix BV team!
Congratulations 🍾
Congratulations team Synaffix BV on this exciting licensing agreement for the development of a ML-designed ADC!